UNICREDIT BANK/CALL/ELI LILLY & CO/1150/0.1/14.01.26 | Real-time BOERSE MUENCHEN 05:40:54 2024-06-07 EDT | ||
| 5.76 EUR | 0.00% |
|
| Current month | +6.27% | ||
| 1 month | +38.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 5.76 | 0.00% |
| 24-06-06 | 5.76 | 0.00% |
| 24-06-05 | 5.76 | +0.52% |
| 24-06-04 | 5.73 | +1.06% |
| 24-06-03 | 5.67 | +4.61% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 05:40 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4LBN |
| ISIN | DE000HD4LBN7 |
| Date issued | 2024-04-12 |
| Strike | 1,150 $ |
| Maturity | 2026-01-14 (587 Days) |
| Parity | 10 : 1 |
| Emission price | 4.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.85 € |
|---|---|
| Lowest since issue | 3.59 € |
| Spread | 0.86 € |
| Spread % | 13.74% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
853.8
USD
Spread / Average Target
+1.97%
- Stock Market
- Warrants
- Warrant
